Market Place
Sourcing Support
Nature Highlights Stratis® DNA Vaccine For Hantaviruses
10 Dec 2024 //
BUSINESSWIRE
Cyrus Biotech to Present Protein Engineering & IgG Protease Data
11 Nov 2024 //
BUSINESSWIRE
EpiVax And CUBRC Awarded $2M FDA Contract For Control Peptides
24 Oct 2024 //
PR NEWSWIRE
Dr. Tom Zhang Presents At Immunogenicity & Bioassay Summit
16 Oct 2024 //
BUSINESSWIRE
AbbVie`s ovarian cancer therapy succeeds in mid-stage trial
07 Jun 2024 //
REUTERS
Genprex Doses First SCLC Patient In Reqorsa+Tecentriq Acclaim-3 Study
14 May 2024 //
PR NEWSWIRE
Gyros Introduces Rodent ADA Kit For Preclinical Immunogenicity
02 May 2024 //
BUSINESSWIRE
In less than 3 months, AbbVie closes $10.1B buyout of ImmunoGen
12 Feb 2024 //
FIERCE PHARMA
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 Feb 2024 //
BUSINESSWIRE
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 Jan 2024 //
BUSINESSWIRE
Filing reveals how AbbVie`s $10B ImmunoGen offer won out
02 Jan 2024 //
FIERCE PHARMA
ImmunoGen Presents Findings from Phase 1b/2 Study of Pivekimab Sunirine at ASH
10 Dec 2023 //
BUSINESSWIRE
FDA Grants Priority Review of ImmunoGen’s Supplemental BLA for ELAHERE
05 Dec 2023 //
BUSINESSWIRE
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 Dec 2023 //
BUSINESSWIRE
AbbVie to buy ImmunoGen for $10.1 billion to boost cancer drug portfolio
01 Dec 2023 //
REUTERS
ImmunoGen Announces Webcast of Presentation
02 Nov 2023 //
BUSINESSWIRE
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 Nov 2023 //
BUSINESSWIRE
ImmunoGen Announces EMA Acceptance of MAA for Mirvetuximab Soravtansine
27 Oct 2023 //
BUSINESSWIRE
Strength Seen in ImmunoGen (IMGN): Can Its 11.7% Jump Turn into More Strength?
25 Oct 2023 //
FINANCE YAHOO
ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2023 Results
19 Oct 2023 //
BUSINESSWIRE
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
29 Sep 2023 //
BUSINESSWIRE
ELAHERE Shows Progression-Free Survival Regardless of Prior PARPi Exposure
28 Sep 2023 //
BUSINESSWIRE
ImmunoGen Appoints Lauren White as Senior VP and Chief Financial Officer
18 Sep 2023 //
BUSINESSWIRE
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
18 Sep 2023 //
BUSINESSWIRE
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 Sep 2023 //
BUSINESSWIRE
ImmunoGen, Takeda Partner to Commercialize ELAHERE in Japan
28 Aug 2023 //
CONTRACT PHARMA
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 Aug 2023 //
BUSINESSWIRE
ImmunoGen Announces Departure of Anna Berkenblit, Chief Medical Officer
31 Jul 2023 //
BUSINESSWIRE
ImmunoGen Announces Webcast of Presentation at Canaccord Genuity Conference
27 Jul 2023 //
BUSINESSWIRE
ImmunoGen Announces Multi-Target Agreement with ImmunoBiochem
24 Jul 2023 //
BUSINESSWIRE
ImmunoGen Announces Conference Call to Discuss Its Second Quarter 2023 Results
17 Jul 2023 //
BUSINESSWIRE
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 Jul 2023 //
BUSINESSWIRE
ImmunoGen Presents Updated Findings from CADENZA Trial of Pivekimab Sunirine
09 Jun 2023 //
BUSINESSWIRE
ELAHERE® Demonstrates 35% Reduction in the Risk of Death in Ovarian Cancer
04 Jun 2023 //
BUSINESSWIRE
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 Jun 2023 //
BUSINESSWIRE
ImmunoGen Announces Webcast of Presentation and Q&A at Jefferies Conference
24 May 2023 //
BUSINESSWIRE
ImmunoGen Announces Closing of Public Offering and Full Exercise
09 May 2023 //
BUSINESSWIRE
ImmunoGen Announces Results from the Phase 3 MIRASOL Trial
09 May 2023 //
BUSINESSWIRE
ImmunoGen reports positive top-line data from ovarian cancer therapy trial
05 May 2023 //
CLINICAL TRIALS ARENA
ImmunoGen Announces Pricing of Upsized Public Offering of Common Stock
04 May 2023 //
BUSINESSWIRE
ELAHERE® Demonstrates Overall Survival Benefit in the Phase 3 MIRASOL Trial
03 May 2023 //
PRESS RELEASE
ImmunoGen Announces Proposed Public Offering of Common Stock
03 May 2023 //
PRESS RELEASE
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 May 2023 //
PRESS RELEASE
Janssen gets priority review for prostate cancer; ImmunoGen reports Q1 sales
28 Apr 2023 //
ENDPTS
ImmunoGen Reports Recent Progress and First Quarter 2023 Financial Results
28 Apr 2023 //
BUSINESSWIRE
ImmunoGen Appoints Isabel Kalofonos as Senior Vice President and CMO
24 Apr 2023 //
BUSINESSWIRE
ImmunoGen Announces Conference to Discuss First Quarter 2023 Operating Results
13 Apr 2023 //
BUSINESSWIRE
ImmunoGen Announces Loan Financing for Up to $175M with Pharmakon Advisors
06 Apr 2023 //
BUSINESSWIRE
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 Apr 2023 //
BUSINESSWIRE
ImmunoGen Presents Additional Efficacy Data from the SORAYA Trial
27 Mar 2023 //
BUSINESSWIRE
Vertex pays ImmunoGen $15M to pair ADCs with CRISPR therapy
02 Mar 2023 //
FIERCE BIOTECH
ImmunoGen Announces Agreement with Vertex for ImmunoGen`s ADC Technology
01 Mar 2023 //
BUSINESSWIRE
ImmunoGen Reports Recent Progress and 2022 Financial Results
01 Mar 2023 //
BUSINESSWIRE
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 Mar 2023 //
BUSINESSWIRE
ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences
22 Feb 2023 //
BUSINESSWIRE
ImmunoGen Announces Conference Call to Discuss Its 2022 Operating Results
15 Feb 2023 //
BUSINESSWIRE
ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences
01 Feb 2023 //
BUSINESSWIRE
ImmunoGen Announces Susan Altschuller on FMLA Leave; Interim CFO Appointed
29 Dec 2022 //
BUSINESSWIRE
ImmunoGen Announces Webcast of Presentation and Q&A at 41st Annual J.P. Morgan
27 Dec 2022 //
BUSINESSWIRE
Biosion Announces Collaboration with ImmunoGen to Create Antibody-Drug Conjugate
13 Dec 2022 //
PRNEWSWIRE
